One To Watch: Ruling On AZ’s First-In-Class Anemia Drug Roxadustat Expected Shortly
Label Warning Will Be Key
AstraZeneca is in pole position to open up the HIF-PH inhibitor market – but GSK has a rival in the wings.
You may also be interested in...
HIF-PHI inhibitor failed to show non-inferiority to ESAs in the primary cardiovascular safety endpoint of a Phase III program for the treatment of anemia due to chronic kidney disease.
Strong results in non-dialysis patients are a particular boost for AZ and its partner, Fibrogen.
A rush of additional orders from countries around the world has boosted the company’s prospects, and fueled its ambitions beyond COVID-19.